Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes
About this study
This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.
- Condition
- Diabete Type 2, Cardio Vascular Disease
- Sponsor
- Weill Cornell Medical College in Qatar
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 6
- Minimum age: 18 years
- Study condition: Diabete Type 2, Cardio Vascular Disease
- Males and females
- Older than 18 years of age
- Willingness to participate in the study and provide written consent form
- Consent to having peripheral blood withdrawals and urine collection for the study requirement.
Exclusion 5
- Unable to meet the inclusion criteria
- Type I diabetes, MODY diabetes or other form of diabetes
- Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to).
- Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis).
- Evidence of malignancy within the past 5 years
Where
1 site, 1 recruiting
Hamad Medical Corporation
Doha, Qatar
Potential match only. Final eligibility is determined by the study team.